Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.